Comparative analysis: FAB and WHO classification of acute myeloid leukemia
10.3781/j.issn.1000-7431.2008.04.018
- Author:
Lan XU
1
Author Information
1. Department of Hematology
- Publication Type:Journal Article
- Keywords:
Diagnosis, differential;
Leukemia, myeloid, acute;
Prognosis
- From:
Tumor
2008;28(4):346-349
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To make a comparative study on the differential diagnosis of the acute myeloid leukemia based on French-American-British Cooperative Group (FAB) and World Health Organization (WHO) standard. Methods: The 118 patients were recruited who were diagnosed with de novo AML. All cases were re-classified according to FAB and WHO classification standard. The median survival time and overall survival rate were recorded for prognosis evaluation. Results: Based on WHO classication standard, there were 35 AML patients (33.7%) with recurrent cytogenetic abnormalities, 21 patients (20.2%) with multilineage dysplasia, and 2 patients (1.9%) with therapy-related AML,and 46 patients (44.2%) AML not otherwise categorized. The 3-year survival rate were (75.1 ± 7.8)%, (47.4 ± 13.9) %, (50.0 ± 35.4)%, and (54.9 ± 10.0)% in different groups based on WHO standard. The difference was significant (P <0.001). Different karyotypes of chromosome had significant effects on the prognosis of AML. The median OS rate was (87.4 ±6.9)% for patients with good prognosis, (69.3 ±7.3)% for patients with moderate prognosis, and (19.6 ± 10.9)% for patients with poor prognosis. The difference was significant (P <0.001). Conclusion: Our study results suggest that classification of primary AML patients according to the WHO standard was more effective for evaluating progression and prognosis of AML.